Showing results (1-10 of 40) with videos related to
Sort By:
Pageof 4
Cancer Research|April 29, 2026
Shaping CDK4/6 inhibitor resistance: BRCA2 germline alterations bias towards RB1 inactivationFabiana Napolitano, Ariella B HankerCancer Cell|March 11, 2025
A CDK4-selective inhibitor puts the brakes on cancer cellsChang-Ching Lin, Ariella B HankerCancer Discovery|March 15, 2019
Challenges for the Clinical Development of PI3K Inhibitors: Strategies to Improve Their Impact in Solid TumorsAriella B Hanker, Virginia Kaklamani, Carlos L ArteagaOncotarget|January 27, 2018
Genomic alterations of ERBB receptors in cancer: clinical implicationsRosalin Mishra, Ariella B Hanker, Joan T GarrettCancer Cell|April 15, 2020
Overcoming Endocrine Resistance in Breast CancerAriella B Hanker, Dhivya R Sudhan, Carlos L ArteagaJournal of Molecular Signaling|August 18, 2009
Romidepsin inhibits Ras-dependent growth transformation of NIH 3T3 fibroblasts and RIE-1 epithelial cells independently of Ras signaling inhibitionAriella B Hanker, Kevin D Healy, Jean Nichols, et al.Breast Cancer Research and Treatment|November 3, 2016
Transcriptome- and proteome-oriented identification of dysregulated eIF4G, STAT3, and Hippo pathways altered by PIK3CA <sup>H1047R</sup> in HER2/ER-positive breast cancerFeixiong Cheng, Junfei Zhao, Ariella B Hanker, et al.Methods in Enzymology|April 1, 2008
Tools to study the function of the Ras-related, estrogen-regulated growth inhibitor in breast cancerAriella B Hanker, Staeci Morita, Gretchen A Repasky, et al.Breast Cancer Research and Treatment|January 22, 2016
Trastuzumab improves tumor perfusion and vascular delivery of cytotoxic therapy in a murine model of HER2+ breast cancer: preliminary resultsAnna G Sorace, C Chad Quarles, Jennifer G Whisenant, et al.Cancer Research|July 5, 2023
Acquired Secondary HER2 Mutations Enhance HER2/MAPK Signaling and Promote Resistance to HER2 Kinase Inhibition in Breast CancerArnaldo Marín, Abdullah Al Mamun, Hima Patel, et al.Pageof 4